Monday, May 19, 1997
At the beginning of the year, AutoImmune Inc. investors looked forward
to several milestones to give proof that oral tolerance therapy would bring drugs to
market for both multiple sclerosis and rheumatoid arthritis. However, AIMM last week
reported a "positive trend" but not significant results for two Phase II trials
of Colloral chicken collagen for RA, news which followed disappointing Phase III results
last month for Myloral bovine myelin for MS (see BioCentury Extra April 22, 1997).
After the Myloral results, AIMM (Lexington, Mass.) said that it planned
to conserve its resources and push Colloral forward. That is still the plan, according to
President and CEO Robert Bishop; however, the next step depends on data analysis and
upcoming meetings with AIMM's clinical consultants.